FGF23 Level and Intima‐Media Thickness Are Elevated From Early Stages of Chronic Kidney Disease

Abstract

Considering high cardiovascular (CV) risk in chronic kidney disease (CKD), the aim of this crosssectional study was to assess the association between carotid intima-media thickness (IMT) and fibroblast growth factor (FGF) 23 as important players in CV pathophysiology. Eighty-seven patients with mean estimated glomerular filtration rate 40.1 mL/min per 1.73 m 2 were involved. FGF23 and IMT were elevated from early stages of CKD. Mean IMT value was 1.10 ± 0.20 mm, being significantly elevated starting from early CKD, showing no correlation with FGF23 (r = À0.01, P = À0.91). Unlike the FGF23 level that followed worsening of kidney function, IMT was increasing only in the initial CKD stages, with no further increase from CKD stage 3 on. Although we found no direct association between current use of vitamin D and statin therapy, this may be associated with the sustained reference values of lipid and vitamin D status under treatment that further preclude worsening of IMT in patients with advanced CKD.

Carotid Intima-Media Thickness: A Surrogate Marker for Cardiovascular Disease in Chronic Kidney Disease Patients

“…Elevation of fibroblast growth factor 23 (FGF 23), which studies have found to be the earliest detected serum abnormality of CKD-MBD (chronic kidney disease-mineral and bone disorder) have also been linked with CVD in CKD patients. 57 These tools are unavailable for the benefits of our patients. However, CIMT, which is a cheap, available and noninvasive investigation tool, is of importance in a developing nation like Nigeria with limited resources, the practicality of which has also been described by other studies 37 and hence its utility as substitute marker for CVD in CKD patients in this part of the world.…”

Risk Factors for Carotid Artery Disease and Chronic Kidney Disease: Same or Unique?

“…Residual risk still persists in CKD patients. The recent study by Figurek et al presented elevated levels of FGF23 in the early stages of CKD .…”

The Complexity of FGF23 Effects on Cardiomyocytes in Normal and Uremic Milieu

“…Thus, a reliable biomarker that could estimate CV risk and mortality should be established. Hence, FGF23 was found as a sensitive biomarker elevated in early CKD [51] suitable for timely estimation of CV risk and therapeutical response in order to possibly prevent CV events and decrease mortality in those patients. Nowadays, many clinical trials reported that FGF23 is very close to being introduced into the clinical routine.…”